NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related concerns between U.S. and China. The Dow Jones Industrial Average increased 0.16 percent to close at 25,502.18, while the S&P 500 Index has gained 0.35 percent to close at 2,850.40. The Nasdaq Composite Index climbed 0.61 percent to close at 7,859.68.
According to senior portfolio manager at TCW, Diane Jaffee, "Earnings growth has been great in the second quarter, but that has been countered by the signs that tariffs have moved from rhetoric into action and are impacting global supply chain."
RDI Initiates Coverage on:
Editas Medicine, Inc.
Ligand Pharmaceuticals Inc.
Editas Medicine's stock moved 1.43% higher Monday, to close the day at $29.09. The stock recorded a trading volume of 820,694 shares, which was below its three months average volume of 1,004,396 shares. In the last year, Editas Medicine's shares have traded in a range of 17.35 - 45.02. The share price has gained 67.67% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $35.50 is below its 200-day moving average of $35.60. Shares of Editas Medicine have fallen roughly 23.33 percent in the past month and are down 5.34 percent year-to-date.
Access RDI's Editas Medicine, Inc. Research Report at:
On Monday, shares of Ligand Pharmaceuticals recorded a trading volume of 305,512 shares, which was below the three months average volume of 343,596 shares. The stock ended the day 0.76% higher at $226.74. The share price has fallen 3.53% from its 52 week high with a 52 week trading range of 121.22 - 235.04. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $214.96 is above its 200-day moving average of $180.09. Shares of the company are trading at a Price to Earnings ratio of 102.83. Shares of Ligand Pharmaceuticals have gained roughly 4.65 percent in the past month and are up 65.59 percent year-to-date.
Access RDI's Ligand Pharmaceuticals Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani,
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.